Addition of KISQALI to drug plan in Quebec expands access to treatment for metastatic breast cancer
- Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer
KISQALI??is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. KISQALI??was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals. About Novartis in Advanced Breast Cancer
Novartis tackles breast cancer with advanced science, collaboration and a passion for transforming patient care. We've taken a bold approach to our research by including patient populations often neglected in clinical trials, identifying new pathways or mutations that may play a role in disease progression and developing therapies that not only maintain, but also improve, quality of life for patients. Our priority over the past 30 years and today is to deliver treatments proven to improve and extend lives for those diagnosed with advanced breast cancer. About Novartis Pharmaceuticals Canada Inc.?
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2018, the company invested?$52 millionin research and development in?Canada. Located in?Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. employs approximately 1,000 people in?Canada?and is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. For further information, please consult?www.novartis.ca. KISQALI is a registered trademark. References
__________________________ |
1?KISQALI?, Product Monograph, November 26, 2018. Available at:?www.novartis.ca/kisqalimonograph. Accessed on July 15, 2019. |
2?Canadian Cancer Society. What is Metastatic Cancer? Available at:?http://www.cancer.ca/en/cancer-information/cancer-type/metastatic-cancer/metastatic-cancer/?region=on. Accessed on July 15, 2019. |
3?Canadian Breast Cancer Network. What is Metastatic Breast Cancer? Available at:?https://www.cbcn.ca/en/what_is_mbc. Accessed on July 15, 2019. |
4?Canadian Breast Cancer Network and Rethink Breast Cancer. Living with Metastatic Breast Cancer in Canada. Available at:?https://www.cbcn.ca/web/default/files/public/Reports/Metastatic%20Breast%20Cancer%20In%20Canada%20Report%20June%202013%20-%20English.pdf. Accessed on July 15, 2019. |
5?Canadian Cancer Society. Canadian Cancer Statistics, a 2018 special report on cancer incidence by stage. Available at:?www.cancer.ca/Canadian-Cancer-Statistics-2018-EN. Accessed on July 15, 2019. |
6?KISQALI?, Patient Medication Information, November 26, 2018. Available at?https://www.novartis.ca/en/our-products/pharmaceuticals#ui-id-1=10. Accessed on July 15, 2019 |